Clinical Trial Update: Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection

View source ↗

Summary

A completed clinical trial evaluating switching to a raltegravir plus abacavir/lamivudine regimen in people with controlled HIV-1 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Epzicom (abacavir/lamivudine)
• Isentress (Raltegravir)

Snippet

Sponsor: Fundacion SEIMC-GESIDA | Conditions: HIV Infections | Status: COMPLETED